Julide Tok Celebi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Julide Tok Celebi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
David N. Silvers
Department of Dermatology, Mailman School of Public Health, Columbia University, New York, New York
5 shared publications- Melissa Gill
Department of Pathology, Columbia University, New York, New York, USA
4 shared publications David A. Lee
Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA
2 shared publications- Ertan Yilmaz
Department of Dermatology and Venereology, Akdeniz University School of Medicine, Antalya, Turkey
2 shared publications Georg Brunner
Department of Cancer Research, Skin Cancer Center Hornheide, Münster, Germany
2 shared publicationsJason A. Cohen
Department of Pathology, Mailman School of Public Health, Columbia University, New York, New York
2 shared publications
Latest Publications
- 1 October 2012
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 10 (10) , 1265-1270
GAB2—a Scaffolding Protein in Cancer
Adaptor or scaffolding proteins mediate protein–protein interactions that drive the formation of protein complexes. Grb2-associated binding protein 2 (GAB2) scaffolding protein is an intermediary molecule that links plasma membrane receptor signaling including receptor tyrosine kinases with the downstream effectors, such as protein tyrosine phosphatase, nonreceptor type 11 (SHP2), p85 subunit of phosphoinositide-3 kinase (PI3-K), phospholipase C-gamma 1 (PLC-γ), v-crk sarcoma virus CT10 (CRK), Src homology 2 domain containing transforming protein 1 (SHC), and SH2 containing inositol phosphatase (SHIP). Although, well described in signal transduction, its role in cancer has recently been emerging especially in leukemia, breast and ovarian cancer, and melanoma. GAB2 is essential for two major signal transduction pathways in cancer, the PI3-K-AKT and extracellular signal-regulated kinase (ERK) signaling pathways, and thus regulates a number of key cellular processes. This review focuses on structure and function of GAB2, its regulatory proteins, emerging role in cancer, and potential as a therapeutic target. Mol Cancer Res; 10(10); 1265–70. ©2012 AACR.
- 1 October 2012
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 10 (10) , 1265-1270
GAB2—a Scaffolding Protein in Cancer
Adaptor or scaffolding proteins mediate protein–protein interactions that drive the formation of protein complexes. Grb2-associated binding protein 2 (GAB2) scaffolding protein is an intermediary molecule that links plasma membrane receptor signaling including receptor tyrosine kinases with the downstream effectors, such as protein tyrosine phosphatase, nonreceptor type 11 (SHP2), p85 subunit of phosphoinositide-3 kinase (PI3-K), phospholipase C-gamma 1 (PLC-γ), v-crk sarcoma virus CT10 (CRK), Src homology 2 domain containing transforming protein 1 (SHC), and SH2 containing inositol phosphatase (SHIP). Although, well described in signal transduction, its role in cancer has recently been emerging especially in leukemia, breast and ovarian cancer, and melanoma. GAB2 is essential for two major signal transduction pathways in cancer, the PI3-K-AKT and extracellular signal-regulated kinase (ERK) signaling pathways, and thus regulates a number of key cellular processes. This review focuses on structure and function of GAB2, its regulatory proteins, emerging role in cancer, and potential as a therapeutic target. Mol Cancer Res; 10(10); 1265–70. ©2012 AACR.
- Open Access
- 27 August 2012
- Published by Springer Nature in Oncogene
- Vol. 32 (31) , 3627-3637
GAB2 induces tumor angiogenesis in NRAS-driven melanoma
GAB2 is a scaffold protein with diverse upstream and downstream effectors. MAPK and PI3K signaling pathways are known effectors of GAB2. It is amplified and overexpressed in a variety of human tumors including melanoma. Here we show a previously undescribed role for GAB2 in NRAS-driven melanoma. Specifically, we found that GAB2 is co-expressed with mutant NRAS in melanoma cell lines and tumor samples and its expression correlated with metastatic potential. Co-expression of GAB2WT and NRASG12D in melanocytes and in melanoma cells increased anchorage-independent growth by providing GAB2-expressing cells a survival advantage through upregulation of BCL-2 family of anti-apoptotic factors. Of note, collaboration of GAB2 with mutant NRAS enhanced tumorigenesis in vivo and led to an increased vessel density with strong CD34 and VEGFR2 activity. We found that GAB2 facilitiated an angiogenic switch by upregulating HIF-1α and VEGF levels. This angiogenic response was significantly suppressed with the MEK inhibitor PD325901. These data suggest that GAB2-mediated signaling cascades collaborate with NRAS-driven downstream activation for conferring an aggressive phenotype in melanoma. Second, we show that GAB2/NRAS signaling axis is non-linear and non-redundant in melanocytes and melanoma, and thus are acting independent of each other. Finally, we establish a link between GAB2 and angiogenesis in melanoma for the first time. In conclusion, our findings provide evidence that GAB2 is a novel regulator of tumor angiogenesis in NRAS-driven melanoma through regulation of HIF-1α and VEGF expressions mediated by RAS-RAF-MEK-ERK signaling.
- 27 August 2012
- Published by Springer Nature in Oncogene
- Vol. 32 (31) , 3627-3637
Open AccessGAB2 induces tumor angiogenesis in NRAS-driven melanoma
GAB2 is a scaffold protein with diverse upstream and downstream effectors. MAPK and PI3K signaling pathways are known effectors of GAB2. It is amplified and overexpressed in a variety of human tumors including melanoma. Here we show a previously undescribed role for GAB2 in NRAS-driven melanoma. Specifically, we found that GAB2 is co-expressed with mutant NRAS in melanoma cell lines and tumor samples and its expression correlated with metastatic potential. Co-expression of GAB2WT and NRASG12D in melanocytes and in melanoma cells increased anchorage-independent growth by providing GAB2-expressing cells a survival advantage through upregulation of BCL-2 family of anti-apoptotic factors. Of note, collaboration of GAB2 with mutant NRAS enhanced tumorigenesis in vivo and led to an increased vessel density with strong CD34 and VEGFR2 activity. We found that GAB2 facilitiated an angiogenic switch by upregulating HIF-1α and VEGF levels. This angiogenic response was significantly suppressed with the MEK inhibitor PD325901. These data suggest that GAB2-mediated signaling cascades collaborate with NRAS-driven downstream activation for conferring an aggressive phenotype in melanoma. Second, we show that GAB2/NRAS signaling axis is non-linear and non-redundant in melanocytes and melanoma, and thus are acting independent of each other. Finally, we establish a link between GAB2 and angiogenesis in melanoma for the first time. In conclusion, our findings provide evidence that GAB2 is a novel regulator of tumor angiogenesis in NRAS-driven melanoma through regulation of HIF-1α and VEGF expressions mediated by RAS-RAF-MEK-ERK signaling.
- 1 June 2011
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 64 (6) , 1185-1186
A melanoma subtype: Uveal melanoma
- 1 June 2011
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 64 (6) , 1185-1186
A melanoma subtype: Uveal melanoma
- Open Access
- 1 July 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (13) , 4288-4291
GAB2 Amplifications Refine Molecular Classification of Melanoma
Purpose: Gain-of-function mutations in BRAF, NRAS, or KIT are associated with distinct melanoma subtypes with KIT mutations and/or copy number changes frequently observed among melanomas arising from sun-protected sites, such as acral skin (palms, soles, and nail bed) and mucous membranes. GAB2 has recently been implicated in melanoma pathogenesis, and increased copy numbers are found in a subset of melanomas. We sought to determine the association of increased copy numbers of GAB2 among melanoma subtypes in the context of genetic alterations in BRAF, NRAS, and KIT. Experimental Design: A total of 85 melanomas arising from sun-protected (n = 23) and sun-exposed sites (n = 62) were analyzed for copy number changes using array-based comparative genomic hybridization and for gain-of-function mutations in BRAF, NRAS, and KIT. Results:GAB2 amplifications were found in 9% of the cases and were associated with melanomas arising from acral and mucosal sites (P = 0.005). Increased copy numbers of the KIT locus were observed in 6% of the cases. The overall mutation frequencies for BRAF and NRAS were 43.5% and 14%, respectively, and were mutually exclusive. Among the acral and mucosal melanomas studied, the genetic alteration frequency was 26% for GAB2, 13% for KIT, 30% for BRAF, and 4% for NRAS. Importantly, the majority of GAB2 amplifications occurred independent from genetic events in BRAF, NRAS, and KIT. Conclusions:GAB2 amplification is critical for melanomas arising from sun-protected sites. Genetic alterations in GAB2 will help refine the molecular classification of melanomas.
- 1 July 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (13) , 4288-4291
Open AccessGAB2 Amplifications Refine Molecular Classification of Melanoma
Purpose: Gain-of-function mutations in BRAF, NRAS, or KIT are associated with distinct melanoma subtypes with KIT mutations and/or copy number changes frequently observed among melanomas arising from sun-protected sites, such as acral skin (palms, soles, and nail bed) and mucous membranes. GAB2 has recently been implicated in melanoma pathogenesis, and increased copy numbers are found in a subset of melanomas. We sought to determine the association of increased copy numbers of GAB2 among melanoma subtypes in the context of genetic alterations in BRAF, NRAS, and KIT. Experimental Design: A total of 85 melanomas arising from sun-protected (n = 23) and sun-exposed sites (n = 62) were analyzed for copy number changes using array-based comparative genomic hybridization and for gain-of-function mutations in BRAF, NRAS, and KIT. Results:GAB2 amplifications were found in 9% of the cases and were associated with melanomas arising from acral and mucosal sites (P = 0.005). Increased copy numbers of the KIT locus were observed in 6% of the cases. The overall mutation frequencies for BRAF and NRAS were 43.5% and 14%, respectively, and were mutually exclusive. Among the acral and mucosal melanomas studied, the genetic alteration frequency was 26% for GAB2, 13% for KIT, 30% for BRAF, and 4% for NRAS. Importantly, the majority of GAB2 amplifications occurred independent from genetic events in BRAF, NRAS, and KIT. Conclusions:GAB2 amplification is critical for melanomas arising from sun-protected sites. Genetic alterations in GAB2 will help refine the molecular classification of melanomas.
- Open Access
Influence of age on survival in childhood spitzoid melanomas
BACKGROUND.: Melanoma occurring during childhood and adolescence is rare. Although a few limited studies suggest that the prognosis of childhood melanomas is similar to those in adults, and is dependent on the initial stage of the tumor, there is controversy with respect to the biologic behavior of childhood melanomas. Spitzoid melanoma is a subtype of melanoma with distinct clinical and histopathologic features. The prognosis of spitzoid melanoma in children, despite metastasis, has been suggested to be better than that observed in adults; however, this assertion remains controversial. Whereas a number of spitzoid melanomas with regional lymph node metastasis with no further progression have been reported, cases leading to widespread metastasis and fatal outcomes are also well documented.METHODS.: A retrospective review of the literature was conducted between 1949 and 2006. A total of 82 cases of spitzoid melanoma with regional and/or widespread metastasis that occurred in children, 17 years of age and under, were selected for the analysis.RESULTS.: The 5‐year survival rate in children diagnosed with metastatic spitzoid melanomas between 0 and 10 years of age was 88% compared with 49% in those between 11 and 17 years of age.CONCLUSIONS.: The findings support the notion that younger age (≤10) may be associated with longer survival in children with metastatic spitzoid melanomas. Cancer 2007. © 2007 American Cancer Society.
Open AccessInfluence of age on survival in childhood spitzoid melanomas
BACKGROUND.: Melanoma occurring during childhood and adolescence is rare. Although a few limited studies suggest that the prognosis of childhood melanomas is similar to those in adults, and is dependent on the initial stage of the tumor, there is controversy with respect to the biologic behavior of childhood melanomas. Spitzoid melanoma is a subtype of melanoma with distinct clinical and histopathologic features. The prognosis of spitzoid melanoma in children, despite metastasis, has been suggested to be better than that observed in adults; however, this assertion remains controversial. Whereas a number of spitzoid melanomas with regional lymph node metastasis with no further progression have been reported, cases leading to widespread metastasis and fatal outcomes are also well documented.METHODS.: A retrospective review of the literature was conducted between 1949 and 2006. A total of 82 cases of spitzoid melanoma with regional and/or widespread metastasis that occurred in children, 17 years of age and under, were selected for the analysis.RESULTS.: The 5‐year survival rate in children diagnosed with metastatic spitzoid melanomas between 0 and 10 years of age was 88% compared with 49% in those between 11 and 17 years of age.CONCLUSIONS.: The findings support the notion that younger age (≤10) may be associated with longer survival in children with metastatic spitzoid melanomas. Cancer 2007. © 2007 American Cancer Society.
- Open Access
Are all melanomas the same?
BACKGROUND: Although the majority of melanomas demonstrate high rates of mutations in B‐RAF or N‐RAS that result in constitutive activation of the mitogen‐activated protein kinase‐signaling pathway, emerging data suggest molecular differences among melanoma subtypes. In this study, the authors evaluated the contribution of B‐RAF and N‐RAS mutations to the pathogenesis of Spitzoid melanomas.METHODS: In total, 33 Spitzoid melanomas were analyzed for clinical and pathologic characteristics as well as for hot‐spot mutations in the B‐RAF and N‐RAS genes. In the majority of patients (28 of 33 melanomas), the tumors were confined to the skin with no evidence of metastasis (average follow‐up, 32.5 mos). There were five metastasizing melanomas (5 of 33 tumors) with regional or systemic spread.RESULTS: Of 33 Spitzoid melanomas, only 1 showed the V600E mutation in the B‐RAF gene (1 of 33 tumors; 3%). It was noteworthy that none of the metastatic Spitzoid melanomas (0 of 5 tumors; 0%), of which 2 resulted in fatal outcomes, demonstrated mutations in B‐RAF or N‐RAS.CONCLUSIONS: In contrast to the majority of cutaneous melanomas, activating hot‐spot mutations in B‐RAF or N‐RAS were not involved in the pathogenesis of Spitzoid melanoma. These data suggested that Spitzoid melanoma is a distinct form of melanoma with unknown genes and/or signaling pathways involved in its development. Cancer 2006. © 2006 American Cancer Society.
Open AccessAre all melanomas the same?
BACKGROUND: Although the majority of melanomas demonstrate high rates of mutations in B‐RAF or N‐RAS that result in constitutive activation of the mitogen‐activated protein kinase‐signaling pathway, emerging data suggest molecular differences among melanoma subtypes. In this study, the authors evaluated the contribution of B‐RAF and N‐RAS mutations to the pathogenesis of Spitzoid melanomas.METHODS: In total, 33 Spitzoid melanomas were analyzed for clinical and pathologic characteristics as well as for hot‐spot mutations in the B‐RAF and N‐RAS genes. In the majority of patients (28 of 33 melanomas), the tumors were confined to the skin with no evidence of metastasis (average follow‐up, 32.5 mos). There were five metastasizing melanomas (5 of 33 tumors) with regional or systemic spread.RESULTS: Of 33 Spitzoid melanomas, only 1 showed the V600E mutation in the B‐RAF gene (1 of 33 tumors; 3%). It was noteworthy that none of the metastatic Spitzoid melanomas (0 of 5 tumors; 0%), of which 2 resulted in fatal outcomes, demonstrated mutations in B‐RAF or N‐RAS.CONCLUSIONS: In contrast to the majority of cutaneous melanomas, activating hot‐spot mutations in B‐RAF or N‐RAS were not involved in the pathogenesis of Spitzoid melanoma. These data suggested that Spitzoid melanoma is a distinct form of melanoma with unknown genes and/or signaling pathways involved in its development. Cancer 2006. © 2006 American Cancer Society.
- Open Access
- 4 November 2005
- Published by BMJ in Journal of Medical Genetics
- Vol. 42 (11) , 811-819
Genetics of skin appendage neoplasms and related syndromes
In the past decade the molecular basis of many inherited syndromes has been unravelled. This article reviews the clinical and genetic aspects of inherited syndromes that are characterised by skin appendage neoplasms, including Cowden syndrome, Birt–Hogg–Dube syndrome, naevoid basal cell carcinoma syndrome, generalised basaloid follicular hamartoma syndrome, Bazex syndrome, Brooke–Spiegler syndrome, familial cylindromatosis, multiple familial trichoepitheliomas, and Muir–Torre syndrome.
- 4 November 2005
- Published by BMJ in Journal of Medical Genetics
- Vol. 42 (11) , 811-819
Open AccessGenetics of skin appendage neoplasms and related syndromes
In the past decade the molecular basis of many inherited syndromes has been unravelled. This article reviews the clinical and genetic aspects of inherited syndromes that are characterised by skin appendage neoplasms, including Cowden syndrome, Birt–Hogg–Dube syndrome, naevoid basal cell carcinoma syndrome, generalised basaloid follicular hamartoma syndrome, Bazex syndrome, Brooke–Spiegler syndrome, familial cylindromatosis, multiple familial trichoepitheliomas, and Muir–Torre syndrome.
- 1 January 2005
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 30 (1) , 68-70
Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome
Atypical mole syndrome is a sporadic or an inherited condition with an increased risk of melanoma. Germline mutations in the CDKN2A, ARF, CDK4 and somatic mutations in the PTEN and BRAF genes have been associated with melanoma. In this study, we evaluated genes associated with familial and sporadic melanoma for mutations in 28 probands with the atypical mole syndrome. No sequence alterations in the coding regions or in the splice junctions of CDKN2A, ARF, CDK4, PTEN or BRAF were identified. These data suggest that genes evaluated in this study are unlikely to be candidate genes for atypical mole syndrome and support the notion that unknown susceptibility gene/s for this disease exist.
- 1 January 2005
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 30 (1) , 68-70
Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome
Atypical mole syndrome is a sporadic or an inherited condition with an increased risk of melanoma. Germline mutations in the CDKN2A, ARF, CDK4 and somatic mutations in the PTEN and BRAF genes have been associated with melanoma. In this study, we evaluated genes associated with familial and sporadic melanoma for mutations in 28 probands with the atypical mole syndrome. No sequence alterations in the coding regions or in the splice junctions of CDKN2A, ARF, CDK4, PTEN or BRAF were identified. These data suggest that genes evaluated in this study are unlikely to be candidate genes for atypical mole syndrome and support the notion that unknown susceptibility gene/s for this disease exist.
- Open Access
Genetic similarities between Spitz nevus and Spitzoid melanoma in children
BACKGROUND: Melanoma in children is rare. Diagnosis of the subtype of melanoma known as Spitzoid melanoma can be extremely challenging in this age group. Spitzoid melanoma clinically and histopathologically resembles a benign melanocytic proliferation referred to as Spitz nevus. In some cases, distinction between the two is impossible. Initial misdiagnoses of Spitzoid melanomas as Spitz nevi, thus leading to fatal outcomes, have occurred. The genetic basis and biologic behavior of Spitzoid melanoma is unknown. Although melanoma specimens exhibit high rates of mutation in the B‐RAF and N‐RAS genes, the Spitzoid melanoma subtype has not been evaluated. Spitz nevi have been found to be associated with a low percentage of mutations in the H‐RAS gene; however, the mutational profile of H‐RAS in Spitzoid melanoma is unknown.METHODS: The authors evaluated a unique series of melanomas occurring in prepubescent children that showed Spitz nevus–like histopathology (Spitzoid melanoma). All of the melanomas in the current series have metastasized to lymph nodes, confirming the diagnosis of melanoma. The authors examined these tumors, as well as age‐matched Spitz nevi, for mutations in the B‐RAF, N‐RAS, and H‐RAS genes.RESULTS: Activating hotspot mutations in the B‐RAF, N‐RAS, and H‐RAS genes were not identified in Spitzoid melanoma or Spitz nevus specimens.CONCLUSIONS: There are genetic similarities with respect to the B‐RAF, N‐RAS, and H‐RAS genes between Spitzoid melanoma and Spitz nevi. Such similarities further differentiate these two tumor types from other melanoma subtypes and from melanocytic nevi, respectively. However, mutation analysis of B‐RAF, N‐RAS, and H‐RAS was not useful in differentiating between Spitzoid melanoma and Spitz nevus in children. Cancer 2004. © 2004 American Cancer Society.
Open AccessGenetic similarities between Spitz nevus and Spitzoid melanoma in children
BACKGROUND: Melanoma in children is rare. Diagnosis of the subtype of melanoma known as Spitzoid melanoma can be extremely challenging in this age group. Spitzoid melanoma clinically and histopathologically resembles a benign melanocytic proliferation referred to as Spitz nevus. In some cases, distinction between the two is impossible. Initial misdiagnoses of Spitzoid melanomas as Spitz nevi, thus leading to fatal outcomes, have occurred. The genetic basis and biologic behavior of Spitzoid melanoma is unknown. Although melanoma specimens exhibit high rates of mutation in the B‐RAF and N‐RAS genes, the Spitzoid melanoma subtype has not been evaluated. Spitz nevi have been found to be associated with a low percentage of mutations in the H‐RAS gene; however, the mutational profile of H‐RAS in Spitzoid melanoma is unknown.METHODS: The authors evaluated a unique series of melanomas occurring in prepubescent children that showed Spitz nevus–like histopathology (Spitzoid melanoma). All of the melanomas in the current series have metastasized to lymph nodes, confirming the diagnosis of melanoma. The authors examined these tumors, as well as age‐matched Spitz nevi, for mutations in the B‐RAF, N‐RAS, and H‐RAS genes.RESULTS: Activating hotspot mutations in the B‐RAF, N‐RAS, and H‐RAS genes were not identified in Spitzoid melanoma or Spitz nevus specimens.CONCLUSIONS: There are genetic similarities with respect to the B‐RAF, N‐RAS, and H‐RAS genes between Spitzoid melanoma and Spitz nevi. Such similarities further differentiate these two tumor types from other melanoma subtypes and from melanocytic nevi, respectively. However, mutation analysis of B‐RAF, N‐RAS, and H‐RAS was not useful in differentiating between Spitzoid melanoma and Spitz nevus in children. Cancer 2004. © 2004 American Cancer Society.